


Open Pharma update: March – June 2020

It's been a busy quarter for Open Pharma, with the publication of our 2020 overall and communications plans and the revamp of our four workstreams, namely Workstream 1, Transparency; Workstream 2, Accountability; Workstream 3, Accessibility; and Workstream 4, Discoverability.

Pushing forward with our Accountability workstream, we have had introductory calls with a number of publishers to increase the visibility of ORCID within their journals. Given the impact of COVID-19 on scientific publishing, we have also discussed the use of preprints with a number of organizations and continued to engage with publishers on open access routes for pharma.

At our virtual US roundtable meeting, which took place on 15 June 2020, we welcomed Open Pharma Members and Supporters and other stakeholders in scientific publishing to discuss US perspectives on open access, the ways in which patients access and discover medical information, how we can build trust using ORCID, and attendees' experiences and perspectives on plain language summaries and preprints. Look out for the meeting report coming to our blog and figshare pages soon!

Activities this quarter



Coming up

The Open Pharma team will be initiating a number of research projects to reflect the new workstreams for 2020; these will form the basis for abstract submissions to the 2021 European Meeting of ISMPP and will be supported by the working groups of our Members and Supporters for each workstream.

We are also working hard to revamp the Open Pharma blog page, to ensure that all our content is as accessible and discoverable as possible!

Oxford PharmaGenesis takes part in a number of activities revolving around open science to help Open Pharma gather insight and build a strong network of supporters; these activities go beyond the core Open Pharma plan and are carried out at no cost to Open Pharma.